Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists

This article was originally published in The Gray Sheet

Executive Summary

CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations

You may also be interested in...



Electronic Standards Key To Better Demographic Data In Trials – McClellan

Electronic clinical trial databases under development at the FDA Office of Women's Health will help sponsors design trials that account for gender and other demographic differences among patients, according to Commissioner Mark McClellan

Electronic Standards Key To Better Demographic Data In Trials – McClellan

Electronic clinical trial databases under development at the FDA Office of Women's Health will help sponsors design trials that account for gender and other demographic differences among patients, according to Commissioner Mark McClellan

Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC

Coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have age-related macular degeneration and occult lesions with no classic choroidal neovascularization (CNV) should be restricted to those with small lesions, according to several MCAC panel members

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel